Halozyme appoints new president, CEO
The company has promoted Michael Shepard as the chief scientific officer after having joined the company as vice president of discovery research. Halozyme president and CEO Gregory Frost
BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.